Martha M Sklavos1, Neelam Giri, Pamela Stratton, Blanche P Alter, Ligia A Pinto. 1. Human Papillomavirus Immunology Laboratory (M.M.S., L.A.P.), Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702; Clinical Genetics Branch (N.G., B.P.A.), Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892; and Program in Reproductive and Adult Endocrinology (P.S.), Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland 20814.
Abstract
CONTEXT: In females with Fanconi anemia (FA), infertility is often accompanied by diminished ovarian reserve and hypergonadotropic amenorrhea before the age of 30 years, suggesting primary ovarian insufficiency (POI). POI is typically diagnosed only after perimenopausal symptoms are observed. OBJECTIVE: The objective of the study was to assess whether serum anti-Müllerian hormone (AMH) levels can serve as a cycle-independent marker for the diagnosis of POI in patients with FA. DESIGN AND SETTING: This observational study used the National Cancer Institute's inherited bone marrow failure syndrome cohort at the National Institutes of Health Clinical Center. PARTICIPANTS: The study included 22 females with FA, 20 unaffected female relatives of patients with FA, and 21 unrelated healthy females under 41 years of age. MAIN OUTCOME MEASURE: Serum AMH, a marker of ovarian reserve, was measured in all participants. RESULTS: Females with FA had very low AMH levels (median 0.05 ng/mL; range 0-2.32 ng/mL; P < .001) when compared with unaffected relatives (median 2.10 ng/mL; range 0.04-4.73 ng/mL) and unrelated healthy females (median 1.92 ng/mL; range 0.31-6.64 ng/mL). All patients with FA older than 25 years of age were diagnosed with POI and had undetectable AMH levels. CONCLUSIONS: AMH deficiency appears to be a shared trait across this heterogeneous FA cohort. Substantially reduced AMH levels in females with FA suggest a primary ovarian defect associated with reduced fertility. Measurement of AMH at the time of FA diagnosis and subsequent monitoring of AMH levels at regular intervals may be useful for the timely management of complications related to POI such as subfertility/infertility, osteoporosis, and menopausal symptoms.
CONTEXT: In females with Fanconi anemia (FA), infertility is often accompanied by diminished ovarian reserve and hypergonadotropic amenorrhea before the age of 30 years, suggesting primary ovarian insufficiency (POI). POI is typically diagnosed only after perimenopausal symptoms are observed. OBJECTIVE: The objective of the study was to assess whether serum anti-Müllerian hormone (AMH) levels can serve as a cycle-independent marker for the diagnosis of POI in patients with FA. DESIGN AND SETTING: This observational study used the National Cancer Institute's inherited bone marrow failure syndrome cohort at the National Institutes of Health Clinical Center. PARTICIPANTS: The study included 22 females with FA, 20 unaffected female relatives of patients with FA, and 21 unrelated healthy females under 41 years of age. MAIN OUTCOME MEASURE: Serum AMH, a marker of ovarian reserve, was measured in all participants. RESULTS: Females with FA had very low AMH levels (median 0.05 ng/mL; range 0-2.32 ng/mL; P < .001) when compared with unaffected relatives (median 2.10 ng/mL; range 0.04-4.73 ng/mL) and unrelated healthy females (median 1.92 ng/mL; range 0.31-6.64 ng/mL). All patients with FA older than 25 years of age were diagnosed with POI and had undetectable AMH levels. CONCLUSIONS:AMH deficiency appears to be a shared trait across this heterogeneous FA cohort. Substantially reduced AMH levels in females with FA suggest a primary ovarian defect associated with reduced fertility. Measurement of AMH at the time of FA diagnosis and subsequent monitoring of AMH levels at regular intervals may be useful for the timely management of complications related to POI such as subfertility/infertility, osteoporosis, and menopausal symptoms.
Authors: J R Lo Ten Foe; M L Kwee; M A Rooimans; A B Oostra; A J Veerman; M van Weel; R M Pauli; N T Shahidi; I Dokal; I Roberts; C Altay; E Gluckman; R A Gibson; C G Mathew; F Arwert; H Joenje Journal: Eur J Hum Genet Date: 1997 May-Jun Impact factor: 4.246
Authors: Louise A Brinton; Carolyn L Westhoff; Bert Scoccia; Emmet J Lamb; Michelle D Althuis; Jerome E Mabie; Kamran S Moghissi Journal: Epidemiology Date: 2005-07 Impact factor: 4.822
Authors: B P Alter; C L Frissora; D S Halpérin; M H Freedman; U Chitkara; E Alvarez; L Lynch; B Adler-Brecher; A D Auerbach Journal: Br J Haematol Date: 1991-03 Impact factor: 6.998
Authors: H J van de Vrugt; N C Cheng; Y de Vries; M A Rooimans; J de Groot; R J Scheper; Y Zhi; M E Hoatlin; H Joenje; F Arwert Journal: Mamm Genome Date: 2000-04 Impact factor: 2.957
Authors: John M Gansner; Maureen M Achebe; Kathryn J Gray; Revital Yefidoff-Freedman; Elena Labovitis; Aric Parnes; Jean M Connors; Nathan T Connell; Marie N Discenza; Robert I Handin; Nancy Berliner; Akiko Shimamura; Elizabeth S Ginsburg; Nicole A Smith Journal: Blood Date: 2017-08-10 Impact factor: 22.113
Authors: Anna Petryk; Roopa Kanakatti Shankar; Neelam Giri; Anthony N Hollenberg; Meilan M Rutter; Brandon Nathan; Maya Lodish; Blanche P Alter; Constantine A Stratakis; Susan R Rose Journal: J Clin Endocrinol Metab Date: 2015-01-09 Impact factor: 5.958
Authors: Melissa A Merideth; Laura A Harney; Nina Vyas; Averyl Bachi; Ann Garrity Carr; D Ashley Hill; Louis P Dehner; Kris Ann P Schultz; Douglas R Stewart; Pamela Stratton Journal: Gynecol Oncol Date: 2020-01-15 Impact factor: 5.482
Authors: Elizabeth R H Rizza; John J DiGiovanna; Sikandar G Khan; Deborah Tamura; Jack D Jeskey; Kenneth H Kraemer Journal: J Invest Dermatol Date: 2021-01-09 Impact factor: 8.551